The shadow of generic here competition has repeatedly loomed around copyright’s blockbuster drug, Viagra, sparking questions about the future of related medicinal stakes. While early periods saw significant profits, the patent end has allowed the path for cheaper copies, likely lowering earnings and presenting a significant risk for shareholders